2(b) Sample Clauses

2(b) c Add the amounts from lines 2a and 2b and enter the result on line 2c . .

2(b). Section 5.2(b) of the Warrant Agreement shall be amended as follows: (i) by deleting subsection (x) thereof in its entirety and replacing it with the following new subsection (x):

2(b). Effective upon, and subject only to, the Acceptance, the provisions of Section 10.04(2)(b) of the Indenture are amended by deleting the text of such Section in its entirety and inserting in lieu thereof the phrase “[intentionally omitted].”

2(b). Membership in the Union is separate, apart and distinct from the assumption by one, of his or her equal obligation to the extent that he or she received equal benefits. The Union is required under this Agreement to represent all of the employees in the bargaining unit fairly and equally without regard to whether or not an employee is a member of the Union. The terms of this Agreement have been made for all employees in the bargaining unit and not only for members in the Union, and this Agreement has been executed by the Employer after it has satisfied itself that the Union is the choice of a majority of employees in the bargaining unit.

2(b). If a Key Person becomes unavailable due to illness or change of employment, this clause requires the affected party to find a suitable replacement and address the impact this change in Key Person may have on the Project. If a Key Person is unable to perform the Project in connection with this Agreement due to: ill health or incapacity; or that person having left the employ of a party (including if the person's employment with a party has been terminated for cause), the party must give the other party as much notice as possible and provide information about the proposed replacement and any other implications that are likely to result from the removal or replacement of its Key Person.

2(b). Section 6.2(b) of the Financing Agreement is hereby deleted and replaced with the following:

2(b). Section 9.2(b) of the Original Agreement is hereby deleted and replaced in its entirety with the following Section 9.2(b): (b) Each party agrees that until publication of the results of the Study as permitted under this Agreement each party will have the limited right to use Study Data, whether owned by it or another party, solely for internal research purposes and patient care purposes, and that it will not disclose Study Data to any other person or entity except: (i) as necessary, in a party’s reasonable medical judgment, for the medical care of any research subject, (ii) as necessary for protection of that party’s interests against lawsuits, allegations of scientific misconduct, conflict of interest actions, patent infringement and interference proceedings, (iii) as permitted by this Agreement or the applicable Project Agreement (provided that [***]; for the avoidance of doubt, this subsection (iii) will not limit FHCRC’s rights under subsections (i), (ii), (iv) or (v) of this Section 9.2(b)), (iv) for purposes of publication or public presentation as permitted under Section 10, (v) as required by applicable laws and regulations including laws and regulations of the FDA relating to licensure of Study Products and laws and regulations of the National Institutes of Health (NIH) relating to government grants and contracts, and (vi) with respect to Juno, to develop and advance the commercialization of cellular immunotherapy products (itself or via commercial relationships with third parties), subject to confidentiality restrictions as provided herein and other applicable legal requirements with respect to such data. For clarity, Juno and its Affiliates shall have the irrevocable right to (and to authorize their Sublicensees, contractors and collaborators to) access, use and reference all Study Data [***] in connection with the development and commercialization of [***], subject to confidentiality restrictions as provided herein and other applicable legal requirements with respect to such data. Notwithstanding anything to the contrary in this Agreement (including, without limitation, any confidentiality restrictions), Juno and its Affiliates shall have the irrevocable right to (and to authorize their Sublicensees, contractors and collaborators to) access, use, reference and include any and all Production Data and Study Data, including clinical data, for and in regulatory filings and patent applications (and related correspondence and filings), in connection ...

2(b). At least 30 days prior to the Deferred Payment Date, Buyer shall deliver notice to Sellers of the amount of the Deferred Payment after deducting any amounts that Buyer has elected to offset pursuant to Section 2.8 and Section 6.2(b) (the “Deferred Payment Notice”). For clarity, the amount of the Deferred Payment set forth in the Deferred Payment Notice with respect to the Deferred Equity Consideration shall be a dollar value that will then be used to calculate the number of shares of Buyer Common Stock to be issued to Sellers consistent with the definition of “Buyer Stock Price” hereunder. If Sellers have not given Buyer written notice of their objection to the calculation of the Deferred Payment as set forth in the Deferred Payment Notice by the Deferred Payment Date, then on the Deferred Payment Date, Buyer shall pay the Deferred Payment to the accounts of Sellers via wire transfer of immediately available funds.

2(b). If a retiree or eligible, covered spouse/registered domestic partner drops his/her medical insurance plan for any reason, he/she is not eligible for re-enrollment.

2(b). Section 5.2(b) of the Warrant Agreement shall be amended as follows: (i) by deleting subsection (x) thereof in its entirety and replacing it with the following new subsection (x): (x) securities issued in connection with a Public Offering;” (ii) by appending the following as a new subsection (xi) immediately after new subsection (x) thereof and renumbering the remaining subsections which follow thereafter accordingly: “(xi) 1,000,000 incentive stock options or other share-based award in such amount to Xx. Xxxxx Xxxxxx, current chairman and chief executive officer of the Company, approved at the August 14, 2009 meeting of the Board in consideration for services rendered to the Company;”